Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | DRD4 | P21917 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
| ▸ | ME3 | Q16798 | 5/20 | 0.41 |
| ▸ | ME2 | P23368 | 4/20 | 0.41 |
| ▸ | ME1 | P48163 | 4/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7041242 | 0.83 | MAPT (0.68) | MAPTALDH1A1KDM4EPKMGAA | |
| SCHEMBL3043144 | 0.78 | ALDH1A1 (0.57) | MAPTALDH1A1KDM4EPKMGAA | |
| SCHEMBL657027 | 0.78 | ALDH1A1 (0.57) | MAPTALDH1A1KDM4EPKMGAA | |
| SCHEMBL240624 | 0.77 | ADRB1 (0.57) | MAPTALDH1A1KDM4EGAAMEN1 | |
| SCHEMBL216663 | 0.77 | ALDH1A1 (0.57) | MAPTALDH1A1KDM4EGAAMEN1 | |
| SCHEMBL220360 | 0.77 | HTR3E (0.57) | MAPTALDH1A1KDM4EGAAMEN1 | |
| SCHEMBL7513534 | 0.77 | LTA4H (0.47) | MAPTALDH1A1KDM4EGAAMEN1 | |
| SCHEMBL3183333 | 0.77 | AKR1C3 (0.44) | MAPTALDH1A1GAAMEN1KMT2A | |
| SCHEMBL7106841 | 0.76 | KDM4E (0.61) | MAPTALDH1A1KDM4EPKMGAA | |
| SCHEMBL20748279 | 0.76 | ALDH1A1 (0.58) | MAPTALDH1A1KDM4EPKMGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2301928-A1 | Imidazolyl-pyrimidine compounds for use in the treatment of proliferative disorders | AstraZeneca AB (SE) | 2011-03-30 | — | — | EP | claimed |
| EP-1620399-B1 | INDOLONE-ACETAMIDE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES | UCB PHARMA SA (BE) | 2010-09-22 | — | — | EP | claimed |
| WO-2010022055-A2 | INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | AMGEN INC. (US) | 2010-02-25 | — | — | WO | claimed |
| US-20080280906-A1 | Imidazolyl-Pyrimidine Compounds for Use in the Treatment of Proliferative Disorders | ASTRAZENECA AB (SE) | 2008-11-13 | — | — | US | claimed |
| EP-1912974-A1 | IMIDAZOLYL-PYRIMIDINE COMPOUNDS FOR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS | AstraZeneca AB (SE) | 2008-04-23 | — | — | EP | claimed |
| US-20070043038-A1 | Indolone-acetamide derivatives, processes for preparing them and their uses | UCB, S.A. (BE) | 2007-02-22 | — | — | US | claimed |
| WO-2007015064-A1 | IMIDAZOLYL-PYRIMIDINE COMPOUNDS FOR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2007-02-08 | — | — | WO | claimed |
| EP-1620399-A1 | INDOLONE-ACETAMIDE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES | UCB, S.A. (BE) | 2006-02-01 | — | — | EP | claimed |
| WO-2004087658-A1 | INDOLONE-ACETAMIDE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES | UCB, S.A. (BE) | 2004-10-14 | — | — | WO | claimed |
| EP-0229467-A1 | 1,5-Benzoxathiepin derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1987-07-22 | — | — | EP | claimed |
| US-4672064-A | CARDIOVASCULAR DISORDERS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1987-06-09 | — | — | US | claimed |
| US-20230277501-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | THE JOHNS HOPKINS UNIVERSITY | 2023-09-07 | — | — | US | disclosed |
| US-20230123729-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | AZEVAN PHARMACEUTICALS INC (US) | 2023-04-20 | — | — | US | disclosed |
| US-11628160-B2 | Compositions and methods for treating brain injury | AZEVAN PHARMACEUTICALS, INC. (US) | 2023-04-18 | — | — | US | disclosed |
| US-20230033195-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | THE JOHNS HOPKINS UNIVERSITY | 2023-02-02 | — | — | US | disclosed |
| US-4877878-A | 2-azolylmethyl-2-aryl-1,3-dioxolanes and the salts thereof, processes for the preparation thereof, agents containing same, and the use thereof | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-10-31 | — | — | US | disclosed |
| US-4818758-A | FUNGICIDES | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-04-04 | — | — | US | disclosed |
| US-4751316-A | CARDIOVASCULAR DISORDERS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1988-06-14 | — | — | US | disclosed |
| EP-0229467-A1 | 1,5-Benzoxathiepin derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1987-07-22 | — | — | EP | disclosed |
| US-4672064-A | CARDIOVASCULAR DISORDERS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1987-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280906-A1 | Imidazolyl-Pyrimidine Compounds for Use in the Treatment of Proliferative Disorders | CCNI, MKI67, TYMP | MAPT 3364/4885ALDH1A1 423/4885KDM4E 3188/4885 |
| US-20230277501-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | GRIN2A, CHRNA2, SYNGR2 | MAPT 215/4885ALDH1A1 2177/4885KDM4E 1177/4885 |
| US-20230123729-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | HTT, AVPR2, AVPR1B | MAPT 30/4885ALDH1A1 3383/4885KDM4E 4519/4885 |
| US-11628160-B2 | Compositions and methods for treating brain injury | FABP7, PYGB, CHAT | MAPT 135/4885ALDH1A1 1429/4885KDM4E 3228/4885 |
| US-20070043038-A1 | Indolone-acetamide derivatives, processes for preparing them and their uses | AANAT, TPH2, CYP1A2 | MAPT 387/4885ALDH1A1 308/4885KDM4E 1236/4885 |
| US-20230033195-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | GRIN2D, GRIN2A, SLC18A2 | MAPT 61/4885ALDH1A1 2755/4885KDM4E 3554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.